← Who reports today · Health Care
CRL · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue fell 2.7% y/y to $1.00B, operating margin 11.9% vs 9.7%, net loss $1.5M (vs net income $52.3M a year earlier).
All figures in $M.
| Line item | Amount and change |
|---|---|
| Service revenue | $808 · −3.9% |
| Product revenue | $196 · +2.3% |
| Total revenue | $1,004 · −2.7% |
| Interest income | $1 · −5.9% |
| Net income (loss) attributable to common shareholders | $1.5 · vs $52.3 |
| Cost of services provided | $552 · −5.6% |
| Cost of products sold | $88.7 · −1.7% |
| Selling, general and administrative | $229 · +19.5% |
| Amortization of intangible assets | $14.6 · −77.7% |
| Interest expense | $30.3 · +1.2% |
| Other (expense) income, net | $37.4 · ×243 |
| Provision for income taxes | $53.9 |
| Less: Net income attributable to noncontrolling interests | $0.7 · +96.7% |
Verdict: revenue fell 2.7% y/y to $1.00B, operating margin 11.9% vs 9.7%, net loss $1.5M (vs net income $52.3M a year earlier).
Source and notation
Source: Charles River Laboratories International press release, 8-K EX-99.1 of 08/05/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: CRL, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “CRL Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/crl/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/crl/q2-2026"><img src="https://whoreportstoday.com/t/crl/q2-2026/sankey.png" alt="CRL Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/crl/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/crl/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/crl/q2-2026">CRL Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Operating income was $120M, a 11.9% margin vs 9.7% a year earlier.
- The effective tax rate was 101.4% vs 26.2% a year earlier.
- Diluted EPS was −$0.03 vs $1.06 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
CRL — a contract research company that supplies research models and services to drug developers and runs outsourced discovery, preclinical safety testing and manufacturing support for pharmaceutical and biotech companies, academic institutions and government labs.
It earns money in three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. · Source: annual report (Form 10-K, SEC)
Heads-up
- a net loss in Q2 2026 ($1.5 · vs $52.3)
Net loss for Q2 2026: $1.5M. In the report's figures: costs grew faster than revenue: selling, general and administrative +20% y/y, less: net income attributable to noncontrolling interests +97% y/y. Based on the Q2 2026 report.
The company's report ↗More reports: CVS · Q3 2026 · DGX · Q3 2026 · DHR · Q3 2026 · DVA · Q3 2026 · DXCM · Q3 2026 · ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · all reports